Stock Events

Stock Events

Arrowhead Pharmaceuticals 

$85.50
99
-$0.99-1.14% 12:21 Today

Statistics

Day High
86.61
Day Low
86.41
52W High
95.49
52W Low
27.1
Volume
38,275
Avg. Volume
-
Mkt Cap
12.22B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-1.59
-0.14
1.3
2.75
Expected EPS
-1.591175
Actual EPS
N/A

Financials

-0.2%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
829.45MRevenue
-1.63MNet Income

Analyst Ratings

101.50Average Price Target
The highest estimate is 126.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ARWR. It's not an investment recommendation.
NVIDIA
27
NVDA
Apple
25
AAPL
AMD
23
AMD
Tesla
22
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals is a direct competitor in the RNA interference (RNAi) therapeutic space, targeting similar diseases as Arrowhead.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals competes in the development of RNA-targeted therapies, sharing a focus on genetic and rare diseases.
Moderna
MRNA
Mkt Cap55.09B
Moderna is involved in mRNA therapeutics and vaccines, representing competition in the broader RNA-based treatment market.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes in the mRNA space, particularly in vaccines, but its technology could extend into therapeutic areas overlapping with Arrowhead's interests.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics focuses on RNA-targeted treatments, especially for rare diseases, competing in the genetic medicine field alongside Arrowhead.
Arcturus Therapeutics
ARCT
Mkt Cap431.75M
Arcturus Therapeutics works on mRNA medicines for various diseases, including those in Arrowhead's target areas, making them competitors in RNA-based therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is focused on gene editing, a different but related approach to treating diseases at the genetic level, potentially competing for similar therapeutic indications.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another company working on CRISPR-based gene editing, competing in the genetic medicine space where RNA therapies like Arrowhead's are also relevant.

About

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Show more...
CEO
Christopher R. Anzalone
Employees
711
Country
United States
ISIN
US04280A1007
WKN
000A2AGYB

Listings

XETRA
DE
HDP1.XETRA
SA
BR
A2RR34.SA
STU
DE
HDP1.STU
MU
DE
HDP1.MU

0 Comments

Share your thoughts

FAQ

What is Arrowhead Pharmaceuticals stock price today?▼
The current price of ARWR is $85.50 USD — it has decreased by -1.14% in the past 24 hours. Watch Arrowhead Pharmaceuticals stock price performance more closely on the chart.
What is Arrowhead Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Arrowhead Pharmaceuticals stocks are traded under the ticker ARWR.
Is Arrowhead Pharmaceuticals stock price growing?▼
ARWR stock has risen by +1.86% compared to the previous week, the month change is a -3.46% fall, over the last year Arrowhead Pharmaceuticals has showed a +208.89% increase.
What is Arrowhead Pharmaceuticals market cap?▼
Today Arrowhead Pharmaceuticals has the market capitalization of 12.22B
When is the next Arrowhead Pharmaceuticals earnings date?▼
Arrowhead Pharmaceuticals is going to release the next earnings report on November 30, 2026.
What were Arrowhead Pharmaceuticals earnings last quarter?▼
ARWR earnings for the last quarter are -1.36 USD per share, whereas the estimation was -1.28 USD resulting in a -6.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arrowhead Pharmaceuticals revenue for the last year?▼
Arrowhead Pharmaceuticals revenue for the last year amounts to 829.45M USD.
What is Arrowhead Pharmaceuticals net income for the last year?▼
ARWR net income for the last year is -1.63M USD.
How many employees does Arrowhead Pharmaceuticals have?▼
As of September 04, 2026, the company has 711 employees.
In which sector is Arrowhead Pharmaceuticals located?▼
Arrowhead Pharmaceuticals operates in the Health & Wellness sector.
When did Arrowhead Pharmaceuticals complete a stock split?▼
The last stock split for Arrowhead Pharmaceuticals was on November 17, 2011 with a ratio of 1:10.
Where is Arrowhead Pharmaceuticals headquartered?▼
Arrowhead Pharmaceuticals is headquartered in PASADENA, United States.